Filter Results:
(1,487)
Show Results For
- All HBS Web
(1,487)
- People (1)
- News (333)
- Research (794)
- Multimedia (8)
- Faculty Publications (573)
Show Results For
- All HBS Web
(1,487)
- People (1)
- News (333)
- Research (794)
- Multimedia (8)
- Faculty Publications (573)
- 17 Apr 2024
- Blog Post
New Venture Competition 2024: Business and Environment Ventures
individual cow health and behavior, empowering farmers and providing peace of mind as they make better high-value livestock management decisions on breeding, disease, and feed programs. EnergAI - Aron Sass (MBA 2025), Balint Varga -... View Details
- 19 Feb 2020
- News
Capitol Ideas to Combat Climate Change
organized by the HBS Business & Environment Initiative and the HBS Club of Washington, DC. The expert panel featured voices from the energy, environmental, and governmental sectors; attendees from fields as diverse as education, health... View Details
Keywords: April White; photos by Jack Conroy
- 30 Mar 2015
- News
Leveraging the power of yes
programs as well as its efforts to distill and disseminate best practices by understanding the true social impact of investing in early-stage companies that provide affordable access to agricultural inputs, high-quality education, clean energy, View Details
- 01 Jun 2023
- News
Turning Point: Sum of the Parts
mother’s norm of doing what you can to help others. Hoping to also satisfy my father, I applied to HBS in the spirit of kaizen. Being admitted promised to change my life in many positive ways, but I felt out of place as a former barrio teacher among classmates who had... View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- June 9, 2023
- Article
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." New England Journal of Medicine 386, no. 23 (June 9, 2023): 2157–2159.
- April 2018 (Revised September 2018)
- Case
Impact Investing for Cancer
By: Richard G. Hamermesh and Matthew G. Preble
It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer... View Details
Keywords: Impact Investing; Investment; Health Disorders; Philanthropy and Charitable Giving; Decision Choices and Conditions
Hamermesh, Richard G., and Matthew G. Preble. "Impact Investing for Cancer." Harvard Business School Case 818-068, April 2018. (Revised September 2018.)
- 19 May 2022
- News
Leading to Salvation
I didn’t quite want to let it go. And it turned out, I met a man named Michael Noonan. Michael manages all the buildings for Hennepin County. North Point Health and Wellness is a big health center. JH:... View Details
- Profile
Jonathon Bunt
bones of a new business.” Immediately after graduation, he returned to the San Francisco start-up and then, after a few months, formed a company of his own: Humble Brands. “It’s about beauty and health from within,” Jonathon says. “We... View Details
- Spring 2021
- Article
Corporate Resilience and Response During COVID-19
By: Alex Cheema-Fox, Bridget LaPerla, George Serafeim and Hui (Stacie) Wang
The coronavirus pandemic caused a sharp market decline while raising heterogeneous responses across companies related to their employees, supply chain, and repurposing of operations to provide needed products and services. We study whether during the 2020 COVID-19... View Details
Keywords: ESG; COVID-19; Coronavirus; Crisis Response Plans; Crisis; ESG (Environmental, Social, Governance) Performance; ESG Ratings; Leadership & Corporate Accountability; Big Data; Machine Learning; Investor Behavior; Institutional Investors; Corporate Performance; Health Pandemics; Crisis Management; Corporate Social Responsibility and Impact; Human Capital; Supply Chain; Operations; Leadership; Corporate Accountability; Institutional Investing; Performance
Cheema-Fox, Alex, Bridget LaPerla, George Serafeim, and Hui (Stacie) Wang. "Corporate Resilience and Response During COVID-19." Journal of Applied Corporate Finance 33, no. 2 (Spring 2021): 24–40.
- 11 Dec 2018
- First Look
New Research and Ideas, December 11, 2018
2018 Oxford University Press Food Citizenship: Food System Advocates in an Era of Distrust By: Goldberg, Ray A. Abstract—The global food system is the largest segment of the world's economy. As agribusiness-studies pioneer Ray Goldberg suggests, it is also the largest... View Details
Keywords: Dina Gerdeman
- March 2017
- Case
Cantel Medical
By: John R. Wells and Gabriel Ellsworth
Cantel Medical Corporation provided infection prevention and control products and services for patients, caregivers, and other healthcare providers. In 2016, Cantel generated sales of $665 million and net profits of $60 million, double the levels of five years earlier.... View Details
Keywords: Cantel; Charles Diker; Furniture Industry; Matrix Organization; Acquisition; Mergers and Acquisitions; Business Conglomerates; Business Units; Business Growth and Maturation; Business Organization; For-Profit Firms; Chemicals; Profit; Revenue; Geographic Scope; Multinational Firms and Management; Health; Health Care and Treatment; Business History; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Organizational Structure; Problems and Challenges; Research and Development; Opportunities; Strategy; Adaptation; Business Strategy; Competitive Strategy; Corporate Strategy; Diversification; Expansion; Information Technology; Health Industry; Health Industry; Health Industry; Health Industry; Health Industry; Health Industry; United States; New Jersey
Wells, John R., and Gabriel Ellsworth. "Cantel Medical." Harvard Business School Case 717-482, March 2017.
- 15 Aug 2006
- First Look
First Look: August 15, 2006
expect bankers to have been less central than in Mexico and, perhaps, the United States. Second, I test if the availability of financing alternatives, like a well-developed bond market in Brazil, reduced the average importance of... View Details
Keywords: Sean Silverthorne
- September 2011
- Teaching Note
Tengion: Bringing Regenerative Medicine to Life (TN)
By: Elie Ofek and Natalie Kindred
Teaching Note for 510031. View Details
- 06 Sep 2024
- Blog Post
Harvard Business School Announces 2024 Goldsmith Fellows
effort to create a network of individuals committed to working in social enterprise. The 2024 Goldsmith Fellows are: Princess Aghayere. Princess is co-founder and director of finance for Rebound Liberia, a nonprofit organization dedicated... View Details
- 01 Jun 2007
- News
Mission Possible
“Rudy contends that if we can identify the other ten or twelve genes that are players, we can give the biotech industry so many more shots to come up with a therapy,” explains McCance, who, along with his cofounders, is privately View Details
- 18 Feb 2010
- News
A Mission to Improve Patients' Lives
- Article
Unhealthy Consumerism: The Challenge of Trading Off Price and Quality in Healthcare
By: Kate Barasz and Peter A. Ubel
Over the last decade, healthcare in many parts of the world has shifted toward a more patient-centric, consumeristic model, marked by an emphasis on choice and a proliferation of typical consumer-facing information (e.g., price and quality data). However, while the... View Details
Keywords: Medical Decision-making; Choice; Health Care and Treatment; Quality; Price; Consumer Behavior; Decision Making
Barasz, Kate, and Peter A. Ubel. "Unhealthy Consumerism: The Challenge of Trading Off Price and Quality in Healthcare." Behavioural Public Policy 2, no. 1 (May 2018): 41–55.
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Pharmaceutical Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- 03 Dec 2018
- Research & Ideas
How Companies Can Increase Market Rewards for Sustainability Efforts
nutrition or health categories. Yet investor momentum differed drastically: Domino’s scored a 15 to Cheesecake Factory’s 87 (out of a 100) in TruValue Labs's sentiment metrics, driven by lower evaluations for customer welfare as well as... View Details
Keywords: by Rachel Layne